TREATMENT OF AIDS RELATED ORAL CANDIDIASIS

皮肤粘膜念珠菌病是艾滋病病毒最常见的表现之一 感染发生在高达84%的艾滋病毒感染者中。虽然 局部和全身抗真菌剂用于治疗这些感染， 它们并没有根除殖民化， 念珠菌对主要系统性抗真菌药物的耐药率增加 剂. 光动力疗法（PDT）是一种涉及使用光动力疗法的方式。 光敏剂和激光产生氧自由基， 癌细胞、细菌、病毒和真菌的破坏。 在医学实践中常用的几种染料都具有优异的光动力学性能 试剂即，亚甲蓝和甲苯胺蓝。这些药物在 与适当波长的光相结合， 体外破坏唑类耐药念珠菌。拟议 研究将试图建立PDT治疗的可行性， 局部染料作为治疗皮肤粘膜念珠菌病的方法 动物模型，证明有效性、病例和最低发病率 这种治疗。 拟定商业应用： 该研究的长期目标是发展PDT 使用局部染料作为主要治疗的治疗装置， HIV感染者皮肤粘膜念珠菌病。由于这种治疗 与局部和全身抗真菌药物不同的作用机制 抗生素，它也将减少发展的重大问题， 真菌耐药性

Mucocutaneous candidiasis is one of the most common manifestations of HIV infection occurring in up to 84% of HIV infected patients. Although topical and systemic antifungal agents are used to treat these infections, they do not eradicate colonization and have resulted in an alarmingly increasing rate of candidal resistance to major systemic antifungal agents. Photodynamic therapy (PDT) is a modality that involves the use of a photosensitizing agent and laser light to create oxygen radicals resulting in the destruction of cancer cells, bacteria, viruses as well as fungi. Several dyes commonly used in medical practice are excellent photodynamic agents i.e., methylene blue and toluidene blue. These agents in combination with the appropriate wavelength of light have resulted in the destruction of azole drug resistant candida species in vitro. The proposed research will attempt to establish the feasibility of PDT treatment with topical dyes as a means of treatment of mucocutaneous candidiasis in an animal model, demonstrating the effectiveness, case and minimal morbidity of this treatment. PROPOSED COMMERCIAL APPLICATION: The longterm objective of the proposed research is to develop PDT treatment devices with topical dyes as a primary treatment for mucocutaneous candidiasis in HIV infected patients. As this treatment has a different mechanism of action than topical and systemic antifungal antibiotics, it will also reduce the significant problem of developing fungal drug resistance.